Lv2
108 积分 2022-04-20 加入
Can multispecific biologics break the efficacy ceiling?
15天前
已完结
Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody
16天前
已完结
IL-2 upgrades show promise at ASCO
18天前
已完结
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease
1个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
1个月前
已完结
Understanding the therapeutic toolkit for inflammatory bowel disease
1个月前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
1个月前
已完结
Link between TNF blockers and rare lymphoma
1个月前
已完结
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
2个月前
已完结
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
2个月前
已完结
皖公网安备34019202002308
